Advisory Panel Appointments

Billam PLC
21 June 2000

                                  BILLAM PLC
                                       
        Appointment to the panel of advisors to the Board of Billam plc

Dr  George Morris and Charles Breese FCA were today appointed to the panel  of
advisors to the Board of Billam Plc.  The directors of Billam stated  that  it
is their intention to assemble a strong multidisciplinary panel which will not
only generate and appraise dealflow for itself but will also seek to act as  a
specialist  filter  for  commercial  organisations  where  this  facility   is
currently not available.

The  Company  intends  to announce further appointments shortly  to  both  the
advisory panel and Board of directors.





Dr. George S. MORRIS

EDUCATION

Wandsworth Comprehensive School, London, and Perse School, Cambridge

King's College, University of London; BSc (Hons) Plant Biochemistry (1978) and
PhD  in Plant Biochemistry (1982) Title; Computer Assisted Analysis of Protein
and Non-protein Amino Acids in Plant of  the Family Leguminosae

EXPERIENCE

Currently Dr G S Morris is a Consultant with Close Brothers Corporate  Finance
in  London  U.K and Close Brothers Equity Markets in Paris, France.  Where  is
advising  on  valuation for IPOs secondary offerings. Private equity  and  M&A
transactions  both technologically and financially. He is also  assisting  the
Close  Brothers group with analysis in his area of experience. This is a  role
he has been performing since the end of January 2000 on temporary bases.

1996-2000 QUARTZ CAPITAL PARTNERS LIMITED; Director - Life Sciences; A  start-
up  European  investment  bank. Responsible for building  the  company's  life
sciences division both from research and transactional perspectives in private
and  public  equity IPOs and M&A activities, and has undertaken  transactional
activities in Europe, the U.S.A. and Australia.

1995-1996       BEESON GREGORY ltd; (Stockbrokers) Consultant to the company
on biotechnology transactions in the UK and Europe.

1988-1996  ADVANCED  TECHNOLOGIES (CAMBRIDGE) LTD; Senior  Research  Scientist
then  Project  Leader Developed and implemented a programme  exploiting  plant
biotechnology  for  the  flavour and fragrance industries  scientifically  and
commercially.

Instigated and managed programmes aimed at the alteration of various  chemical
factors in targeted crop plants by genetic engineering.

Managed many of the company's biochemical and chemical functions.
Set   up  and  ran  collaborative  programmes  with  academic  and  commercial
organisations throughout Europe.

1987-1988 UNIVERSITY COLLEGE LONDON, DEPARTMENT OF CHEMISTRY; Post Doctoral
Research Fellow
Managed  a  programme  to  produce chemicals and  biological  compounds  using
advanced  biotechnology for industrial, agricultural and medical applications.
Research conducted under commercial sponsorship raised in conjunction with the
professor.

1986-1987 KINGS COLLEGE LONDON, DEPARTMENT OF BIOLOGY; Post Doctoral Research
Associate
Exploited  tissue  culture  and  genetic  manipulation  techniques   for   the
production of high value-added chemicals from low cost starting materials.

1982-1986  GUYS  HOSPITAL MEDICAL SCHOOL (UMDS) DEPARTMENT OF  MEDICINE;  Post
Doctoral Research Scientist
An  academic  laboratory  within a major teaching  hospital,  studying  inborn
errors  of  metabolism in humans. Developed systems for the  determination  of
pharmaceuticals  and  their  metabolites  under  the  aberrant  conditions  of
inherited  errors  of  metabolism.  Several became  standard  within  hospital
situations.

Worked on the development of pre-natal diagnosis of metabolic errors.

Assisted management accountants in the establishment of national reference lab
for the range of disorders specialised in by the laboratory.

1981-1982 LAURENCE, PRUST & Co (stockbrokers); Institutional Research Analyst
As  an  analyst  in  the  UK  institutional research  department  focusing  on
pharmaceuticals and Head of Corporate Finance on biotechnology projects.

ADDITIONAL INFORMATION

A named author on around forty referred papers and a named inventor on patents
currently  being processed and granted. Throughout the scientific periods  has
conducted   consultancy   projects  in  the  fields   of   biotechnology   and
pharmaceuticals  for City of London corporate stockbroking firms  and  smaller
commercial companies and is a SFA Registered Representative. Also sits on  the
European Commission's panel on Biotechnology and financing as an expert and is
regularly  asked to be a conference speaker and participant in  this  area  of
experience.   Has  undertaken  numerous  continuing  professional  development
courses  covering finance and general management as well as in specific  areas
related to science & technology, statistics and project management





Charles Breese FCA

Qualified as a chartered accountant with Grant Thornton

Subsequently spent thirteen years with KPMG up to 1982.

June 1982- joined Larpent Newton, a venture capital fund manager, and became
managing director in 1986.

2000 onwards
Key features of the investment philosophy developed specifically to meet
today's market requirements by Charles at Larpent Newton are as follows:
-    focus on ambitious technology driven companies, both quoted and unquoted
-    all investee companies have to operate within the B2B sector and sell
     products and/or services delivering demonstrable value
-    combining industrialists with fund managers to assist with the
     development of investee companies.

The above filter is an effective tool for identifying businesses which are
likely to prosper across a broad range of B2B activities in the new business
environment created by developments in communications technologies. Examples
of established companies with which Charles has been involved are Fuel-Tech
(NASDAQ), Plasmon, Snackhouse and TLS Range.

Charles agreed to join the Billam plc Investment Committee because Billam
plc's investment approach accords with the approach described above.

Key directorships
    Oxford Technology 2 Venture Capital Trust plc.
    Oxford Technology Venture Capital Trust plc
    M R Sentire Limited
    Larpent Newton & Co Ltd
    Beaver Holdings Limited



21 June 2000